Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 3
2013 9
2014 6
2015 1
2016 2
2017 3
2018 1
2019 4
2020 4
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

31 results
Results by year
Filters applied: . Clear all
Page 1
Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies.
Pagan F, Hebron M, Valadez EH, Torres-Yaghi Y, Huang X, Mills RR, Wilmarth BM, Howard H, Dunn C, Carlson A, Lawler A, Rogers SL, Falconer RA, Ahn J, Li Z, Moussa C. Pagan F, et al. Among authors: hebron m. J Parkinsons Dis. 2016 Jul 11;6(3):503-17. doi: 10.3233/JPD-160867. J Parkinsons Dis. 2016. PMID: 27434297 Free PMC article. Clinical Trial.
Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial.
Pagan FL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, Yusuf N, Starr NJ, Anjum M, Arellano J, Howard HH, Shi W, Mulki S, Kurd-Misto T, Matar S, Liu X, Ahn J, Moussa C. Pagan FL, et al. Among authors: hebron ml. JAMA Neurol. 2020 Mar 1;77(3):309-317. doi: 10.1001/jamaneurol.2019.4200. JAMA Neurol. 2020. PMID: 31841599 Free PMC article. Clinical Trial.
Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.
Pagan FL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, Yusuf N, Starr NJ, Arellano J, Howard HH, Peyton M, Matar S, Liu X, Fowler AJ, Schwartz SL, Ahn J, Moussa C. Pagan FL, et al. Among authors: hebron ml. Pharmacol Res Perspect. 2019 Mar 12;7(2):e00470. doi: 10.1002/prp2.470. eCollection 2019 Apr. Pharmacol Res Perspect. 2019. PMID: 30906562 Free PMC article. Clinical Trial.
Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease.
Pagan FL, Wilmarth B, Torres-Yaghi Y, Hebron ML, Mulki S, Ferrante D, Matar S, Ahn J, Moussa C. Pagan FL, et al. Among authors: hebron ml. Mov Disord. 2021 Mar;36(3):740-749. doi: 10.1002/mds.28389. Epub 2020 Nov 20. Mov Disord. 2021. PMID: 33215762 Free PMC article. Clinical Trial.
Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases.
Fowler AJ, Hebron M, Balaraman K, Shi W, Missner AA, Greenzaid JD, Chiu TL, Ullman C, Weatherdon E, Duka V, Torres-Yaghi Y, Pagan FL, Liu X, Ressom H, Ahn J, Wolf C, Moussa C. Fowler AJ, et al. Among authors: hebron m. Hum Mol Genet. 2020 Oct 10;29(17):2882-2898. doi: 10.1093/hmg/ddaa177. Hum Mol Genet. 2020. PMID: 32776088 Free PMC article.
Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease.
Turner RS, Hebron ML, Lawler A, Mundel EE, Yusuf N, Starr JN, Anjum M, Pagan F, Torres-Yaghi Y, Shi W, Mulki S, Ferrante D, Matar S, Liu X, Esposito G, Berkowitz F, Jiang X, Ahn J, Moussa C. Turner RS, et al. Among authors: hebron ml. Ann Neurol. 2020 Jul;88(1):183-194. doi: 10.1002/ana.25775. Epub 2020 May 28. Ann Neurol. 2020. PMID: 32468646 Free PMC article.
31 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page